{"id":4253,"date":"2026-10-12T08:32:24","date_gmt":"2026-10-12T08:32:24","guid":{"rendered":"https:\/\/nhdbio.com\/?p=4253"},"modified":"2026-10-12T08:32:24","modified_gmt":"2026-10-12T08:32:24","slug":"oktan-orales-semaglutid-umstellung-drei-monate","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/de\/octane-oral-semaglutide-switch-three-months\/","title":{"rendered":"Umstellung auf orales Semaglutid: Was bedeutet 4.1% Gewichtsverlust in drei Monaten?"},"content":{"rendered":"
\n
\"An
Editorial illustration, not an experimental photograph.<\/figcaption><\/figure>\n

After switching from an injection to an oral tablet, can weight loss continue? The OCTANE study recorded changes in a group of people who actually switched medications. It can help us understand real-world use, but it cannot directly answer which dosage form is better.<\/p>\n

\n

This time we are looking at people who actually switched medications<\/h2>\n

The data announced on September 30 came from the Ro telehealth platform. The participants had overweight or obesity, had previously used injectable semaglutide or tirzepatide, then switched to oral semaglutide and continued using it for three months.<\/p>\n

The researchers looked back at these people's records; they did not randomly divide them into two groups of 'continue injection' and 'switch to oral.' So this is a real-world observational study, not a direct head-to-head comparison of the two dosage forms.<\/p>\n<\/section>\n

\n

4.1% is an average change, not everyone's goal<\/h2>\n

The announcement reported that after three months, average body weight decreased by 4.1%, about 4 kilograms. 40.7% of participants lost at least 5%.[1]<\/a><\/p>\n

Using an easy-to-understand hypothetical example: starting weight of 100 kilograms, a decrease of 4.1% means losing 4.1 kilograms. The actual study's average starting weight was not exactly 100 kilograms, and changes varied from person to person; an average cannot be used as an individual prediction.<\/p>\n<\/section>\n

\n

Why can't oral and injection be seen as simply changing the packaging?<\/h2>\n

After a peptide enters the body, it must remain sufficiently intact to work. Injections bypass some barriers in the gastrointestinal tract, while oral formulations need to address digestion and absorption problems.[1]<\/a><\/p>\n

Therefore, the performance of an oral tablet depends on the entire formulation and the conditions of its use. Putting the same-named peptide raw material into an ordinary capsule does not equal obtaining the oral drug from clinical research, and injection doses cannot simply be converted into oral doses.<\/p>\n<\/section>\n

\n

Could people who stayed for three months differ from those who dropped out?<\/h2>\n

Yes. This analysis required three months of continuous treatment and may not fully reflect those who stopped early. If some people dropped out because of discomfort, cost, or unsatisfactory results, the remaining records may look better.<\/p>\n

Routine platform records may also be incomplete, with some weight and experience data self-reported by users. Feedback in the announcement such as clothing feel and dietary changes can also only be interpreted within the groups for which data are available.<\/p>\n<\/section>\n

\n

What questions does it leave for the next step of research?<\/h2>\n

Longer-term observation of weight, reasons for discontinuation, and adverse reactions is needed, as is a clearer comparison of different pre-switch experiences. How long someone had already used the drug and how much weight they had already lost can both affect later changes.<\/p>\n

So the value of this study is that it provides an early record of medication switching. It does not constitute steps for adjusting medication on one's own, nor does it prove that oral formulations are generally superior to injections.<\/p>\n<\/section>\n

\n

For people who have already lost weight with injections, what is special about their starting point?<\/h2>\n

Their weight at the time they switched may already have been affected by prior treatment. If another group had never used the drug, directly comparing three-month weight-loss percentages would not mean starting from the same starting line.<\/p>\n

Clearer follow-up records should include duration of use before switching, prior weight changes, reasons for switching, and discontinuation information. This information can help determine which conditions the later changes came from.<\/p>\n<\/section>\n